无容量
索拉非尼
医学
肝细胞癌
肿瘤科
内科学
佐剂
癌症
重症监护医学
免疫疗法
作者
Lim Chiew Woon,Lee Joycelyn Jie Xin,Choo Su Pin
标识
DOI:10.1080/14712598.2020.1749593
摘要
Introduction Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide and up to recently, sorafenib was the only approved systemic treatment options. In recent years, many other treatment options have received approval for advanced HCC, including nivolumab, a Programmed-Death-1 (PD-1) inhibitor.Areas covered We review the current treatment landscape of HCC, an overview of the characteristics of nivolumab and current ongoing and completed trials of nivolumab.Expert opinion Nivolumab is generally well tolerated and has modest single-agent activity as a monotherapy in advanced HCC. Further studies are required to better explore its role as part of combination approaches, in adjuvant/neoadjuvant setting, as well as to understand the impact of sequencing of its use with other systemic therapy options.
科研通智能强力驱动
Strongly Powered by AbleSci AI